Genovis EBIT per Share
The EBIT per Share of Genovis (GENO.ST) as of Aug 15, 2026 is 0.42 SEK. In the previous year, EBIT per Share was 0.70 SEK — a change of -40.43% (lower).
Get this data via API
Financial Data API
EBIT per Share
0.42SEK
YoY
-40.43%
Last updated:
EBIT per Share of Genovis is 2026 0.42 SEK. EBIT per Share of Genovis was 2025 0.70 SEK. It decreases by -40.43% lower compared to the previous year.
Access this data via the Eulerpool API
Genovis Stock analysis
What does Genovis do? Genovis AB is a Swedish company that offers biotechnology solutions for drug research and diagnostic industries. The company was founded in Lund, Sweden in 1999 and currently employs over 30 employees.
Genovis began with the development of enzymes for protein-based therapeutics, but over time expanded its business to include enzymes for improved analysis methods in mass spectrometry. Genovis has become a leading provider of innovative enzyme solutions and proteomics tools for biomedical research.
The company's business model is based on providing specially developed enzymes and proteomics tools to companies in drug research and diagnostic industries. Genovis has two main business areas: marketing enzymes and providing peptide synthesis services.
The first business area is the marketing of enzymes for the separation of glycosylated proteins in mass spectrometry. The company develops and produces these enzymes for various applications such as Alzheimer's research, cancer research, and infectious diseases. Genovis is also an important provider of enzymes for the investigation of antibody-drug conjugates used in novel therapeutic approaches.
The second business area is providing peptide synthesis services. The company also has a diversified biotechnology infrastructure and offers analysis and synthesis services for peptides in various fields, such as immunotherapy and diagnostics.
Genovis' product portfolio includes a variety of enzymes that have broad application in drug research and diagnostic industries. This includes enzymes for antibody proteolysis, enzymes for the synthesis of glycoconjugates, and enzymes for conjugated protein analysis.
In addition, the company also offers specialized kits for protein analysis. Genovis kits always include all necessary components such as proteases, buffer systems, and instructions to conduct the offered experiments.
In conclusion, Genovis is a leading company in the biotechnology industry that offers innovative enzyme solutions and proteomics tools for a variety of applications in medical research and diagnostics. With its diversified biotechnology infrastructure and dedicated employees, the company can meet the growing needs of its customers in the science and industry sectors and has become a key partner in the healthcare industry. Genovis is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Genovis stock
EBIT per Share of Genovis is 0.42 SEK in 2026.
EBIT per Share of Genovis changed from 0.70 SEK to 0.42 SEK, representing a -40.43% change. The value is lower than the previous year.
On Eulerpool you can find the complete historical development of EBIT per Share Genovis since 2006 – with annual values, charts, and detailed analysis.
EBIT per Share measures operating profit allocated to each outstanding share.
Access this data via the Eulerpool API
Income Statement — Genovis
All Key Metrics — Genovis
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth